Selective Kv1.3 channel blocker as therapeutic for obesity and insulin resistance

Area of Science:

• Pharmacology
• Metabolic disease
• Ion channel research

Background:

• Obesity is a global epidemic requiring novel pharmacological treatments.
• Voltage-gated potassium channels, specifically Kv1.3, are implicated in metabolic regulation.

Purpose of the Study:

• To investigate the efficacy of ShK-186, a selective Kv1.3 channel blocker, in ameliorating diet-induced obesity and insulin resistance.
• To elucidate the mechanisms underlying ShK-186's effects on energy metabolism and adipose tissue.

Main Methods:

• Administration of ShK-186 to mice fed a high-fat, high-fructose diet or a standard chow diet.
• Assessment of body weight, adiposity, liver health, blood metabolic markers (cholesterol, glucose, HbA1c, insulin, leptin), and insulin sensitivity.
• Analysis of brown adipose tissue activation (glucose uptake, gene expression, energy expenditure) and hepatic lipid metabolism.

Main Results:

• ShK-186 significantly reduced weight gain, adiposity, and fatty liver in mice on the obesity diet.
• Treatment decreased blood cholesterol, glucose, HbA1c, insulin, and leptin levels, while enhancing insulin sensitivity.
• ShK-186 activated brown adipose tissue, increasing energy expenditure and modulating hepatic energy and lipid metabolism, with effects dependent on diet composition.

Conclusions:

• ShK-186 demonstrates significant therapeutic potential for treating obesity and insulin resistance.
• Targeting Kv1.3 channels with blockers like ShK-186 offers a promising pharmacological strategy for metabolic disorders.
• Diet-induced changes in Kv1.3 expression and sensitivity influence the effectiveness of Kv1.3 blockade.